Upcoming Investor Conferences for AnaptysBio
As a prominent player in the biotechnology field, AnaptysBio, Inc. (Nasdaq: ANAB) is focused on developing innovative therapeutics that target autoimmune and inflammatory diseases. Based in San Diego, this clinical-stage company has exciting days ahead as it prepares to engage with investors through a series of high-profile conferences this November and December.
Details on the Conferences
The company has announced participation in several key investor conferences where investors can gain insights into AnaptysBio's development programs and future direction. Here's a closer look at these important events:
Guggenheim's Inaugural Healthcare Innovation Conference
This conference in Boston, MA, is scheduled for November 13. AnaptysBio will be featured in a fireside chat format, which will include one-on-one meetings with investors. This is a fantastic opportunity for stakeholders to learn more about the company's current projects and investment potential.
Stifel 2024 Healthcare Conference
Following the Guggenheim event, AnaptysBio will participate in the Stifel 2024 Healthcare Conference on November 19 in New York, NY. In this setting, attendees can anticipate engaging discussions about the company's strategic vision and therapeutic advancements.
Piper Sandler 36th Annual Healthcare Conference
On December 3, AnaptysBio will take part in the Piper Sandler conference, once again in New York. This annual event gathers industry leaders and investors, providing an ideal platform for AnaptysBio to discuss its ongoing projects and innovations.
Evercore HealthCONx Conference
The final conference of the season for AnaptysBio will be the 7th Annual Evercore HealthCONx Conference in Coral Gables, FL, scheduled for December 4. This event will round off their conference participation, and opportunities for networking with investors will abound.
Webcast Availability
For investors who cannot attend these conferences in person, live webcasts of the fireside chats will be available in the investor section of AnaptysBio's website. Replays of these webcasts will also be accessible for at least 30 days after the events, ensuring that all interested parties have the chance to benefit from the discussions.
About AnaptysBio
AnaptysBio is not just about attending conferences; they are at the forefront of developing groundbreaking therapeutics. Their pipeline includes notable programs like ANB032, targeting BTLA receptors, which is currently under scrutiny in a Phase 2b trial aimed at treating atopic dermatitis. Furthermore, their PD-1 agonist, rosnilimab, is being tested in conjunction with Phase 2b and Phase 2 trials aimed at addressing rheumatoid arthritis and ulcerative colitis respectively. As they continue to innovate, AnaptysBio is also advancing other candidates, such as ANB033 and ANB101, which address critical healthcare needs.
Apart from therapeutic antibodies, AnaptysBio has also developed cytokine antagonists that are ready for out-licensing, including imsidolimab and etokimab, both of which have completed or are nearing completion of important clinical trials. In collaboration with GSK, AnaptysBio has made strides in the immuno-oncology field, showcasing their commitment to providing cutting-edge healthcare solutions.
Contact Information
For more information about AnaptysBio and its innovative projects, interested parties can reach out to:
Nick Montemarano
Senior Director, Investor Relations and Strategic Communications
Phone: 858.732.0178
Email: investors@anaptysbio.com
Frequently Asked Questions
What conferences is AnaptysBio participating in?
AnaptysBio is participating in several conferences, including Guggenheim's Healthcare Innovation Conference, Stifel 2024 Healthcare Conference, Piper Sandler Healthcare Conference, and Evercore HealthCONx Conference.
Where can I watch the presentations?
Live webcasts of the presentations will be available on AnaptysBio's investor website, with replays accessible for 30 days after the events.
What is AnaptysBio focusing on?
AnaptysBio is focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases.
What are some products in AnaptysBio's pipeline?
Some notable products in AnaptysBio's pipeline include ANB032, a BTLA agonist, and rosnilimab, a PD-1 agonist for various inflammatory conditions.
How can I contact AnaptysBio for more information?
You can contact Nick Montemarano at 858.732.0178 or via email at investors@anaptysbio.com for inquiries regarding the company.
